Zobrazeno 51 - 60
of 117
pro vyhledávání: '"Junko Tanizaki"'
Autor:
Shinichiro, Suzuki, Kimio, Yonesaka, Takeshi, Teramura, Toshiyuki, Takehara, Ryoji, Kato, Hitomi, Sakai, Koji, Haratani, Junko, Tanizaki, Hisato, Kawakami, Hidetoshi, Hayashi, Kazuko, Sakai, Kazuto, Nishio, Kazuhiko, Nakagawa
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(20)
Treatment withClones of sotorasib-sensitiveUnbiased screening detected subclonal evolution of
Autor:
Naoki Takegawa, Hidetoshi Hayashi, Hisato Kawakami, Junji Tsurutani, Junko Tanizaki, Kazuhiko Nakagawa, Kimio Yonesaka, Satomi Watanabe, Masayuki Takeda, Koji Haratani, Yoshikane Nonagase
Publikováno v:
Cancer Medicine
HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions pla
Autor:
Jamie A. Saxon, Michael J. Eck, Pasi A. Jänne, T. Kosaka, Jieun Son, Eun Young Park, Hwan Geun Choi, Nathanael S. Gray, Dries De Clercq, Jaebong Jang, Junko Tanizaki
Publikováno v:
Angewandte Chemie International Edition. 57:11629-11633
Exon 20 insertion (Ex20Ins) mutations are the third most prevalent epidermal growth factor receptor (EGFR) activating mutation and the most prevalent HER2 mutation in non-small cell lung cancer (NSCLC). Novel therapeutics for the patients with Ex20In
Autor:
Ryoji, Kato, Hidetoshi, Hayashi, Kazuko, Sakai, Shinichiro, Suzuki, Koji, Haratani, Takayuki, Takahama, Junko, Tanizaki, Yoshikane, Nonagase, Kaoru, Tanaka, Takeshi, Yoshida, Masayuki, Takeda, Kimio, Yonesaka, Hiroyasu, Kaneda, Kazuto, Nishio, Kazuhiko, Nakagawa
Publikováno v:
International journal of clinical oncology. 26(9)
We here applied cancer personalized profiling by deep sequencing (CAPP-seq) to analysis of circulating tumor DNA (ctDNA) to identify resistance mechanisms in osimertinib-treated patients with EGFR T790M-positive non-small cell lung cancer (NSCLC).The
Autor:
Junko Tanizaki, Haruko Daga, Masahiro Morise, Hideaki Mizutani, Tomohiro Sakamoto, Takaaki Sasaki, Chiyo K. Imamura, Keiju Aokage, Shunsuke Teraoka, Yuko Oya, Satoshi Morita, Kenichi Suzuki, Yukiko Nakamura, Takeharu Yamanaka, Kiichiro Ninomiya, Toshiyuki Kozuki, Kaname Nosaki, Yuichi Takiguchi, Toyoaki Hida, Hitomi Nishimoto, Satoru Miura, Satoshi Oizumi, Shinsuke Amano, Yoshitaka Zenke, Hisashi Tanaka, Yasushi Goto, Yusuke Okuma, Kentaro Tanaka, Noriyuki Ebi, Katsuyuki Hotta, Eisaku Miyauchi, Kazuo Hasegawa, O. Yamaguchi, Kazuko Nakajima, Akihiro Tamiya, Hirotsugu Kenmotsu
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100107-(2021)
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100107-(2021)
Patients with NSCLC in East Asia, including Japan, frequently contain EGFR mutations. In 2018, we published the latest full clinical practice guidelines on the basis of those provided by the Japanese Lung Cancer Society Guidelines Committee. The purp
Autor:
Masayuki Takeda, Yosuke Makuuchi, Junko Tanizaki, Kaoru Tanaka, Kazuhiko Nakagawa, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Shigeki Shimizu, Akihiko Ito, Koji Haratani
Publikováno v:
Oncotarget
The second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and ceritinib are standard treatment options for patients with non–small cell lung cancer (NSCLC) positive for ALK fusion genes. However, almost all
Autor:
Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Masayuki Takeda, Kazuhiko Nakagawa, Kazuto Nishio, Koji Haratani, Takayuki Takahama, Junko Tanizaki
Publikováno v:
Oncotarget
Unlike common epidermal growth factor receptor gene (EGFR) mutations that confer sensitivity to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC), mutations in exon 20 of either EGFR or the human EGFR2 gene (HER2) are associated
Autor:
Kazuhiko Nakagawa, Yasutaka Chiba, Kimio Yonesaka, Hiroyasu Kaneda, Yoshikazu Hasegawa, Hidetoshi Hayashi, Yasushi Nakamura, Koji Haratani, Masayuki Takeda, Kaoru Tanaka, Akihiko Ito, Keita Kudo, Junko Tanizaki
Publikováno v:
Journal of Thoracic Oncology. 13:97-105
Objective The aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with NSCLC treated with nivolumab. Methods Univariable and multivariable analyses were performed retrospectively for 134
Autor:
Naoki Takegawa, Junji Tsurutani, Masayuki Takeda, Hidetoshi Hayashi, Takeshi Yoshida, Kimio Yonesaka, Junko Tanizaki, Hisato Kawakami, Satomi Watanabe, Kazuhiko Nakagawa
Publikováno v:
Molecular Cancer Therapeutics. 16:2563-2571
T790M mutation–selective EGFR tyrosine kinase inhibitors (EGFR-TKI) have demonstrated clinical benefits in non–small cell lung cancer (NSCLC) patients harboring T790M mutation, which is the major cause of resistance to EGFR-TKI. However, their ef
Autor:
Hidetoshi Hayashi, Yuuri Hashimoto, Kenji Hirotani, Kazuko Sakai, Hiroki Goto, Hisato Kawakami, Kazuhiko Nakagawa, Maki Kobayashi, Osamu Maenishi, Masanori Funabashi, Masayuki Takeda, Kazuto Nishio, Ryoto Yoshimoto, Takashi Kagari, Junko Tanizaki, Kaoru Tanaka, Kimio Yonesaka
Publikováno v:
Annals of Oncology. 32:S296